A database of FDA approved therapeutic peptides and proteins
ID1028 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel | CompanyImmunex Corp | Physical AppearanceLyophilized powder. | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1029 | ThPPIDTh1005 | NameEtanercept | Peptide SequenceLPAQVAFTPYAPEPGSTCRL Full view | Length255 | Functional ClassificationIIa | DiseaseImmunological | BrandEnbrel Sureclick | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetTumor necrosis factor,Tumor necrosis factor receptor superfamily member 1B,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c,Lymphotoxin-alpha,Low affinity immunoglobulin gamma Fc region re |
ID1038 | ThPPIDTh1007 | NameLeuprolide | Peptide SequencePHWSYLLR Full view | Length8 | Functional ClassificationIIa | DiseaseCancer | BrandEligard | CompanyAtrix Labs/QLT In | Physical AppearanceSuspension | Route of AdministartionSubcutaneous Injection | CategoryAntineoplastic Agents, Hormonal and fertility agents, estrogen antagonists | TargetGonadotropin-releasing hormone receptor |
ID1049 | ThPPIDTh1008 | NamePeginterferon alfa-2a | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPegasys | CompanyHoffman-La Roche Inc | Physical AppearanceSterile, preservative-free, colorless to light yellow injectable solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1064 | ThPPIDTh1011 | NameDarbepoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandAranesp | CompanyAmgen Inc | Physical AppearanceSterile, colorless, preservative-free solution containing polysorbate | Route of AdministartionIntravenousor Subcutaneous administration | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1071 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandBinocrit | CompanySandoz | Physical AppearanceClear colourless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1074 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogen | CompanyAmgen Inc. | Physical AppearanceSterile, colorless liquid | Route of AdministartionSubcutaneous Injection | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1075 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEpogin | CompanyChugai | Physical AppearanceN.A. | Route of AdministartionSubcutaneous or by Intravenous. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1076 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandEprex | CompanyJanssen-Cilag. Ortho Biologics LLC | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1078 | ThPPIDTh1013 | NameEpoetin alfa | Peptide SequenceAPPRLICDSRVLERYLLEAK Full view | Length166 | Functional ClassificationIb | DiseaseHematological | BrandProcrit | CompanyOrtho Biotech | Physical AppearanceSterile, colorless liquid in an isotonic sodium chloride/sodium citrate buffered solution or a sodium chloride/sodium phosphate buffered solution | Route of AdministartionIntravenous(IV) or Subcutaneous (SC) administration. | CategoryAnti-anemic Agents, Hematinics | TargetErythropoietin receptor |
ID1098 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandCalcimar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1100 | ThPPIDTh1014 | NameSalmon Calcitonin | Peptide SequenceCSNLSTCVLGKLSQELHKLQ Full view | Length32 | Functional ClassificationIb | DiseaseOsteological | BrandMiacalcin | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous or Intramuscular Injection | CategoryBone Density Conservation Agents, Antihypercalcemic agents, Anti-osteoporotic agents | TargetCalcitonin receptor |
ID1117 | ThPPIDTh1016 | NamePegfilgrastim | Peptide SequenceMTPLGPASSLPQSFLLKCLE Full view | Length175 | Functional ClassificationIb | DiseaseImmunological | BrandNeulasta | CompanyAmgen Inc. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-neutropenic agents | TargetGranulocyte colony-stimulating factor receptor,Neutrophil elastase |
ID1120 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeucomax | CompanyNovartis | Physical AppearanceSolution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1121 | ThPPIDTh1017 | NameSargramostim | Peptide SequenceAPARSPSPSTQPWEHVNAIQ Full view | Length127 | Functional ClassificationIb | DiseaseImmunological | BrandLeukine | CompanyBerlex Laboratories Inc | Physical AppearanceSterile, preserved (1.1% benzyl alcohol), injectable solution (500 mcg/mL) and also as sterile, white, preservative free lyophilized powder (250 mcg) that requires reconstitution with 1 mL sterile water for Injection | Route of AdministartionSubcutaneous Injection (SC) or Intravenous infusion (IV) | CategoryImmunosuppressive Agents | TargetGranulocyte-macrophage colony-stimulating factor receptor subunit alpha,Interleukin-3 receptor subunit alpha,Cytokine receptor common subunit beta,Syndecan-2,Bone marrow proteoglycan |
ID1135 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandPEG-Intron | CompanySchering Corp | Physical AppearancePowder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1136 | ThPPIDTh1019 | NamePeginterferon alfa-2b | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandUnitron PEG | CompanyN.A. | Physical AppearanceLyophilized powder | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1180 | ThPPIDTh1023 | NameAnakinra | Peptide SequenceMRPSGRKSSKMQAFRIWDVN Full view | Length153 | Functional ClassificationIIa | DiseaseImmunological | BrandKineret | CompanyAmgen Inc | Physical AppearanceSterile, clear, colorless-to-white, preservative free solution | Route of AdministartionSubcutaneous (SC) administration | CategoryImmunosuppressive Agents, Anti-rheumatic agents | TargetInterleukin-1 receptor type 1 |
ID1205 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandHumulin R | CompanyEli Lilly and Company | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous injection in the abdominal wall, the thigh, the gluteal region or in the upper arm and Intravenousadministration of Humulin R (insulin (human recombinant)) U-100 is possible under medical supervision. | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1206 | ThPPIDTh1027 | NameInsulin Regular | Peptide SequenceA-chain:GIVEQCCTSIC< Full view | Length51 | Functional ClassificationIa | DiseaseGenetic/Hormonal | BrandNovolin R | CompanyNovo Nordisk | Physical AppearanceSterile, clear, aqueous, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryAntidiabetic Agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor,Retinoblastoma-associated protein,Cathepsin D,Insulin-degrading enzyme,Neuroendocrine convertase 2,Carboxypeptidase E,Neuroendocrine convertase 1,Protein NOV homolog,Low-density lipoprotein receptor-r |
ID1215 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandMenopur | CompanyN.A. | Physical AppearanceSterile, lyophilized powder which is reconstitution with sterile 0.9% Sodium Chloride Injection. | Route of AdministartionSubcutaneous Injection | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1216 | ThPPIDTh1029 | NameMenotropins | Peptide SequenceAlpha-Chain(LH):APD< Full view | Length222 | Functional ClassificationIb | DiseaseHormonal disorders | BrandRepronex | CompanyN.A. | Physical AppearanceSterile, lyophilized form | Route of AdministartionSubcutaneous or Intramuscular Injection. | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor,Lutropin-choriogonadotropic hormone receptor |
ID1226 | ThPPIDTh1030 | NameInterferon gamma-1b | Peptide SequenceCYCQDPYVKEAENLKKYFNA Full view | Length146 | Functional ClassificationIb | DiseaseImmunological | BrandActimmune | CompanyInterMune Inc | Physical AppearanceSterile, clear, colorless solution | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents | TargetInterferon gamma receptor 1,Interferon gamma receptor 2 |
ID1229 | ThPPIDTh1031 | NameInterferon Alfa-2a, Recombinant | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological | BrandRoferon A | CompanyHoffmann-La Roche Inc | Physical AppearanceSolution | Route of AdministartionSubcutaneous Injection | CategoryN.A. | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1242 | ThPPIDTh1033 | NameOprelvekin | Peptide SequenceGPPPGPPRVSPDPRAELDST Full view | Length177 | Functional ClassificationIb | DiseaseCancer/Haemetological | BrandNeumega | CompanyGenetics Institute Inc | Physical AppearanceSterile, lyophilized powder | Route of AdministartionSubcutaneous injection | CategoryCoagulants and Thrombotic Agents, Anti-neoplastic agents | TargetInterleukin-11 receptor subunit alpha |
ID1252 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucaGen | CompanyNovo Nordisk | Physical AppearanceSterile, lyophilized white powder | Route of AdministartionSubcutaneous, Intramuscular, or Intravenous infusion | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1253 | ThPPIDTh1035 | NameGlucagon recombinant | Peptide SequenceHSQGTFTSDYSKYLDSRRAQ Full view | Length29 | Functional ClassificationIV | DiseaseHormonal/Metabolic/genetic | BrandGlucagon | CompanyEli Lilly | Physical AppearancePowder | Route of AdministartionSubcutaneously or Intramuscularly Injection | CategoryHypoglycemic Agents | TargetGlucagon receptor,Glucagon-like peptide 2 receptor,Glucagon-like peptide 1 receptor |
ID1265 | ThPPIDTh1038 | NameOmalizumab | Peptide SequenceHeavy chain:EVQLVESG Full view | Length243 | Functional ClassificationIIa | DiseaseImmunological | BrandXolair | CompanyGenentech Inc | Physical AppearanceSterile, white, preservative free, lyophilized powde | Route of AdministartionSubcutaneous Injection | CategoryAnti-Allergic Agents, Anti-asthmatic, Immuno-suppressive agents | TargetHigh affinity immunoglobulin epsilon receptor subunit alpha and beta |
ID1269 | ThPPIDTh1039 | NameLutropin alfa | Peptide SequenceAlpha Chain: APDVQDC Full view | Length213 | Functional ClassificationIb | DiseaseHormonal | BrandLuveris | CompanySerono | Physical AppearanceWhite lyophilised pellet withg clear colourless solvent to make solution | Route of AdministartionSubcutaneous (SC) administration | CategoryFertility Agents | TargetLutropin-choriogonadotropic hormone receptor |
ID1275 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog | CompanyEli Lilly | Physical AppearanceSterile, aqueous, clear, and colorless solution | Route of AdministartionSubcutaneous and Intravenous infusion | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1276 | ThPPIDTh1040 | NameInsulin Lispro | Peptide SequenceA chain:GIVEQCCTSICS Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandHumalog KwikPen | CompanyEli Lilly | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1283 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus | CompanySanofi-Aventis | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1284 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus OptiSet | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1285 | ThPPIDTh1041 | NameInsulin Glargine | Peptide SequenceA-chain:GIVEQCCTSICS Full view | Length53 | Functional ClassificationIa | DiseaseHormonal/Metabolic/genetic | BrandLantus SoloStar | CompanyN.A. | Physical AppearanceSolution | Route of AdministartionSubcutaneous injection | CategoryHypoglycemic Agents, Antidiabetic agents | TargetInsulin receptor,Insulin-like growth factor 1 receptor |
ID1316 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseImmunological | BrandHumira | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous administration | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1317 | ThPPIDTh1044 | NameAdalimumab | Peptide SequenceLight-chain:DIQMTQS< Full view | Length230 | Functional ClassificationIc | DiseaseOsteological | BrandHumira Pen | CompanyAbbott Laboratories | Physical AppearanceSterile, preservative-free solution | Route of AdministartionSubcutaneous injection | CategoryImmunosuppressive Agents, Anti-inflammatory, Antirheumatic agents | TargetTumor necrosis factor,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamm |
ID1342 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1343 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandBetaseron | CompanyMerck | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1345 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1346 | ThPPIDTh1049 | NameInterferon beta-1a | Peptide SequenceMSYNLLGFLQRSSNFQCQKL Full view | Length166 | Functional ClassificationIb | DiseaseCancer/Infectious/Immunological | BrandRebif | CompanyMerck | Physical AppearanceSterile solution in a prefilled syringe or REBIF Rebidose autoinjector | Route of AdministartionSubcutaneous Injection | CategoryImmunosuppressive Agents, Antineoplastic, Antiviral, Immunologic factors | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1372 | ThPPIDTh1055 | NameFollitropin beta | Peptide SequenceA Chain: APDVQDCPECT Full view | Length204 | Functional ClassificationIb | DiseaseHormonal disorders | BrandFollistim AQ | CompanyMerck | Physical AppearanceSterile aqueous solution | Route of AdministartionSubcutaneous or Intramuscular administration | CategoryFertility Agents | TargetFollicle-stimulating hormone receptor |
ID1375 | ThPPIDTh1056 | NameVasopressin | Peptide SequenceCYFQNCPRG Full view | Length9 | Functional ClassificationIb | DiseaseHormonal | BrandPitressin | CompanyJHP Pharmaceuticals | Physical AppearanceSterile, aqueous solution of synthetic vasopressin | Route of AdministartionIntramuscular or Subcutaneous use | CategoryAntidiuretic Agents | TargetVasopressin V2 receptor,Vasopressin V1a receptor,Vasopressin V1b receptor |
ID1376 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaseron | CompanyBayer | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1377 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandBetaferon | CompanyBayer | Physical AppearancePowder and solvent that are made upto make solution. | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1378 | ThPPIDTh1057 | NameInterferon beta-1b | Peptide SequenceMSYNLLGFLQRSSNFQSQKL Full view | Length166 | Functional ClassificationIb | DiseaseImmunological | BrandExtavia | CompanyNovartis | Physical AppearanceSterile, white to off-white powder | Route of AdministartionSubcutaneous Injection | CategoryAdjuvants, Immunologic and Immunosuppressive Agents | TargetN.A. |
ID1379 | ThPPIDTh1058 | NameInterferon alfacon-1 | Peptide SequenceCDLPQTHSLGSRRTLMLLAQ Full view | Length165 | Functional ClassificationIb | DiseaseImmunological/Infectious | BrandINFERGEN | CompanyKadmon Pharmaceuticals, LLC. | Physical AppearanceSterile, clear, colorless, preservative-free liquid | Route of AdministartionSubcutaneous Injection | CategoryAntiviral Agents and Immunosuppressive Agents | TargetInterferon alpha/beta receptor 1,Interferon alpha/beta receptor 2 |
ID1381 | ThPPIDTh1059 | NameHyaluronidase | Peptide SequenceMWTGLGPAVTLALVLVVAWA Full view | Length476 | Functional ClassificationIc | DiseaseAdjunct Therapy | BrandHYLENEX | CompanyBaxter Healthcare Corporation | Physical AppearanceSterile, clear, colorless, nonpreserved, ready for use solution. | Route of AdministartionHuman Injection Subcutaneous use | CategoryAdjuvants, Anesthesia and Permeabilizing Agents | TargetN.A. |
ID1382 | ThPPIDTh1060 | NameInsulin, porcine | Peptide SequenceA chain: GIVEQCCTSIC Full view | Length51 | Functional ClassificationIa | DiseaseHormonal/Metabolic | Brandvetsulin | CompanyIntervet Inc (Merck Animal Health) | Physical AppearanceSterile injectable suspension in multidose vials containing 10 mL of 40 IU/mL porcine insulin zinc suspension | Route of AdministartionSubcutaneous Injection | CategoryHypoglycemic Agents | TargetInterferon alpha/beta receptor 2,Interferon alpha/beta receptor 1, Hyaluronan, Transforming growth factor beta-1 |
ID1415 | ThPPIDTh1069 | NamePegvisomant | Peptide SequenceFPTIPLSRLFDNAMLRAHRL Full view | Length191 | Functional ClassificationIIa | DiseaseHormonal | BrandSOMAVERT | CompanyPfizer | Physical AppearanceSterile, white lyophilized powder | Route of AdministartionSubcutaneous Injection | CategoryHormone Replacement Agents | TargetB-lymphocyte antigen CD20,Low affinity immunoglobulin gamma Fc region receptor III-B,Complement C1r subcomponent,Complement C1q subcomponent subunit A,Complement C1q subcomponent subunit B,Complement C1q subcomponent subunit C,Low affinity immunoglobulin gamma Fc region receptor III-A,High affinity immunoglobulin gamma Fc receptor I,Low affinity immunoglobulin gamma Fc region receptor II-a,Low affinity immunoglobulin gamma Fc region receptor II-b,Low affinity immunoglobulin gamma Fc region receptor II-c |
ID1439 | ThPPIDTh1077 | NameUrofollitropin | Peptide SequenceAlpha chain:APDVQDCP Full view | Length203 | Functional ClassificationIb | DiseaseHormonal | BrandBRAVELLE | CompanyFerring Pharmaceuticals Inc. | Physical AppearanceSterile, lyophilized powder used after reconstitution with sterile 0.9% Sodium Chloride Injection | Route of AdministartionIntramuscular and Subcutaneous administration | CategoryFertility Agents | TargetGlutamate carboxypeptidase 2 |